Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

New England Journal of Medicine

Volumn 334, Issue 1, 1996, Pages 1-6

  Mcguire, William P ^a,j   Hoskins, William J ^b,c   Brady, Mark F ^d   Kucera, Paul R ^e   Partridge, Edward E ^f   Look, Katherine Y ^g   Clarke Pearson, Daniel L ^h   Davidson, Martin ⁱ  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Department of Obstetrics Gynecology   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g INDIANA UNIVERSITY   (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ WALTER REED ARMY MEDICAL CENTER   (United States)

^j GOG Administrative Office   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADULT; ALLERGIC REACTION; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0030054309     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199601043340101     Document Type: Article

References (26)

1. Williams CJ, Mead GM, Macbeth FR, et al. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol 1985;3.1455-62.
2. Neijt JP, ten Bokkel Humink WW, van der Burg ME, et al. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984;2:594-600
3. Omura GA, Blessing JA, Ehrlich CE, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 1986;57:1725-30.
4. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 1991;303.884-93.
5. Thigpen JT, Blessing JA, Vance RB, Lambuth BW. Chemotherapy in ovarian carcinoma: present role and future prospects. Semin Oncol 1989;16:58-65.
6. GICOG (Gruppo Interregionale Cooperativo Oncologico Gynecologica) Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adnamycin in advanced ovarian cancer. Gynecol Oncol 1992;45:115-7.
7. Williams CJ, Stewart L, Parmar M, Guthrie D. Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma: the Advanced Ovarian Cancer Trialists Group. Semin Oncol 1992;19:Suppl 2:120-8.
8. Sutton GP, Stehman FB, Einhorn HL, Roth LM, Blessing JA, Ehrlich CE Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 1989;7:223-9.
9. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9.
10. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748-53
11. Rowinsky EK, Gilbert MR, McGuire WP, et al Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991;9:1691-703.
12. McGuire WP. Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma. Gynecol Oncol 1993;51.78-85.
13. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332-1004-14.
14. Blessing JA Design, analysis and interpretation of chemotherapy trials in gynecologic cancer. In: Deppe G, ed. Chemotherapy of gynecologic cancer. 2nd ed. New York: Wiley-Liss, 1990:63-97.
15. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50 163-70.
18. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220.
19. Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952;47:583-621
20. Agresti A. Categorical data analysis. New York: John Wiley, 1990.
21. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC Cardiac disturbances during the administration of taxol J Clin Oncol 1991,9:1704-12.
22. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9.1138-50.
23. McGuire WP, Hoskins WJ, Brady MF, et al. An assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995;13 1589-99.
24. Bookman MA, McGuire WP, Kilpatrick E, et al. Phase I Gynecologic Oncology Group (GOG) study of 3-h and 24-h paclitaxel with carboplatin as initial therapy for advanced epithelial ovarian cancer (OvCA). J Clin Oncol (in press).
25. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12: 2654-66.
26. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines Br J Cancer 1993,68.1104-9.